Supporting faster, cleaner, more efficient pharmaceutical manufacturing processes
Codexis markets enzymes and intermediates to global pharmaceutical manufacturers. Proven Codexis biosolutions are at work improving product purity and yields, reducing production process steps, eliminating toxins from the manufacturing process and reducing the need for capital expenditures.
Tailored enzymes enable targeted chemical processes to manufacture the specific pharmaceutical product our customers require. The results are more efficient manufacturing, lower costs, greater profitability.
Today, Codexis biobased products are in use at more than 50 drug companies around the world. Merck and Codexis have jointly developed a new manufacturing process for sitagliptin, the active ingredient in Januvia® for Type 2 diabetes. In a paper in Science on the project, Merck and Codexis reported a 10-13% increase in overall yield, a 53% increase in productivity and a 19% reduction in total waste. (Science, June 17, 2010)
Codexis is supplying pharmaceutical intermediates for the cholesterol-reducing drug Lipitor® from Pfizer. Codexis won the US EPA Presidential Green Chemistry Challenge Award in 2006 for work with Pfizer, and was the co-recipient in 2010 with Merck.
Codexis customers also include major global manufacturers in generics and contract manufacturing. Codexis is working with Teva, the largest generic drug maker in the world, Albany Molecular Research, Inc. (AMRI), a global contract research and manufacturing organization, and Dainippon Sumitomo Pharma Co., Ltd. (DSP), one of the ten largest Japanese pharmaceutical manufacturers.
For any inquiries, please contact Codexis via email at: